Recently Updated
What changed and when — corrections, retractions, and other meaningful editorial updates, newest first.
Updates
Trial Watch: Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Status changed from "In editorial review" to "Verified".
Trial Watch: Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Status changed from "In editorial review" to "Verified".
FDA approves tovorafenib, the first systemic therapy for BRAF-altered pediatric low-grade glioma
Status changed from "Legacy / Unverified" to "In editorial review".
FDA clears AI-powered second-read tool that catches missed prostate cancers on biopsy
Status changed from "Legacy / Unverified" to "In editorial review".
FDA converts tisotumab vedotin’s accelerated approval to full approval for recurrent or metastatic cervical cancer
Status changed from "Legacy / Unverified" to "In editorial review".
Phase 3 ASCENT-07 trial finds no progression-free-survival benefit for sacituzumab govitecan over chemotherapy in HR-positive breast cancer
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves lifileucel, the first tumor-derived T-cell therapy, for advanced melanoma
Status changed from "Legacy / Unverified" to "In editorial review".
National mortality data show a substantial drop in cervical cancer deaths among HPV-vaccinated women in England
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves epcoritamab, a first-in-class bispecific antibody, for relapsed or refractory large B-cell lymphoma
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves sotorasib plus panitumumab, the first KRAS G12C-targeted combination for colorectal cancer
Status changed from "Legacy / Unverified" to "In editorial review".
A lab-made “molecular glue” reprograms a lymphoma oncogene to trigger cancer-cell self-destruction, in early cell and mouse studies
Status changed from "Legacy / Unverified" to "In editorial review".
FDA grants traditional approval to pirtobrutinib for BTK-inhibitor-pretreated CLL/SLL
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves eflornithine, the first therapy to reduce relapse risk in high-risk pediatric neuroblastoma
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves Breyanzi as the first CAR T-cell therapy for marginal zone lymphoma
Status changed from "Legacy / Unverified" to "In editorial review".
Landmark NHS-Galleri multi-cancer blood-test trial missed its primary goal, but found real gains in earlier-stage detection
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves the first ctDNA-guided adjuvant immunotherapy, for bladder cancer after surgery
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves blinatumomab in the consolidation phase of B-cell precursor acute lymphoblastic leukemia, regardless of MRD status
Status changed from "Legacy / Unverified" to "In editorial review".
A widely-shared case series claiming a veterinary dewormer treats cancer was retracted — for an undisclosed conflict of interest, not disproven data
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit
Status changed from "Legacy / Unverified" to "In editorial review".
Six-year OlympiA data sustain the adjuvant olaparib survival benefit in BRCA-mutated, HER2-negative early breast cancer
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves selpercatinib, the first targeted therapy for young children with RET-altered thyroid cancer
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves Optune Pax, a wearable electric-field device, for locally advanced pancreatic cancer
Status changed from "Legacy / Unverified" to "In editorial review".
Luveltamab tazevibulin showed responses in platinum-resistant ovarian cancer in dose-optimization data; the trial was later terminated
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves zanidatamab for HER2-positive biliary tract cancer, including cholangiocarcinoma
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves the first all-oral combination regimen for older adults with newly diagnosed acute myeloid leukemia
Status changed from "Legacy / Unverified" to "In editorial review".
Lunresertib plus camonsertib produces durable responses in advanced endometrial and ovarian cancer in early trial data
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves perioperative pembrolizumab for head and neck cancer — the first approval for this cancer in 6 years
Status changed from "Legacy / Unverified" to "In editorial review".
Investigational triple-negative breast cancer vaccine shows safety and immune response in phase 1 trial
Status changed from "Legacy / Unverified" to "In editorial review".
Prospective trial finds robotic surgery a safe option for right-sided colon cancer
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves talquetamab, a first-in-class bispecific antibody, for heavily pretreated multiple myeloma
Status changed from "Legacy / Unverified" to "In editorial review".